The People's Ledger
← All Virginia bills

HB483Introduced in the House of Delegates

Prescription Drug Affordability Board; established.

Vetoed

Introduced by Karrie Delaney, District 9

What does this bill do?

Plain-English breakdown

Writing a plain-English summary of this bill… this can take a few seconds the first time.

Official description

Prescription Drug Affordability Advisory Panel established; maximum fair price; annual reports; civil penalties. Directs the Secretary of Health and Human Resources to establish the Prescription Drug Affordability Advisory Panel to conduct data analyses, develop policy recommendations, and identify implementation barriers related to strategies to improve prescription drug affordability, enhance price transparency, and strengthen data collection practices for prescription drugs across public and private payers. The bill requires the Panel to (i) report annually on prescription drug pricing trends and any policy recommendations on legislation to improve prescription drug affordability and (ii) provide quarterly updates on prescription drug pricing trends. The bill requires each pharmacy benefits manager to provide to the Panel, upon request, certain information relating to the dispensation of a referenced drug, as defined in the bill.The bill prohibits prescription drug manufacturers or wholesale distributors permitted or licensed in the Commonwealth from accepting payment at an amount higher than the maximum fair price established by the U.S. Secretary of Health and Human Services pursuant to federal law for the sale of a referenced drug intended for use by individuals in the Commonwealth. Under the bill, an entity that violates such prohibition is subject to a civil penalty of $10,000 per violation. The bill also prohibits a manufacturer subject to its provisions from removing a referenced drug from sale distribution in the Commonwealth for the purpose of avoiding the impact of the bill's rate limitations without providing certain prior notice. Under the bill, a manufacturer that violates such prohibition on removing a referenced drug without the required notice is subject to a civil penalty equal to the greater of $100,000 or the total amount of annual savings for the referenced drug, as determined by the Board of Pharmacy. This bill is identical to SB 271.

Where it stands

Vetoed by Governor

May 19, 2026

How did lawmakers vote?

House of Delegates votes

6 recorded votes · each counted separately

Senate votes

4 recorded votes · each counted separately

House of DelegatesStage: Senate substitute agreed to by House (87-Y 11-N 0-A) · March 12, 2026

87

Yes

11

No

1

Absent or Not Voting

99 delegates recorded in this House of Delegates vote. Colors show vote categories only, not whether a vote was good or bad.

See how each delegate voted

DelegateDistrictVote
Patrick Hope1Yes
Adele McClure2Yes
Alfonso Lopez3Yes
Charniele Herring4Yes
Kirk McPike5Yes
Richard Sullivan6Yes
Karen Keys-Gamarra7Yes
Irene Shin8Yes
Karrie Delaney9Yes
Dan Helmer10Yes

Bill history

  1. Prefiled and ordered printed; Offered 01-14-2026 26104953D

  2. Referred to Committee on Labor and Commerce

  3. Assigned HCL sub: Subcommittee #1

  4. House subcommittee offered

  5. Subcommittee recommends reporting with amendment(s) and referring to Appropriations (5-Y 4-N)

  6. Fiscal Impact Statement from Department of Planning and Budget (HB483)

  7. Reported from Labor and Commerce with amendment(s) and referred to Appropriations (14-Y 8-N)

  8. Assigned HAPP sub: Health & Human Resources

  9. Subcommittee recommends reporting (6-Y 1-N)

  10. Reported from Appropriations (17-Y 5-N)

  11. Read first time

  12. Read second time

  13. committee amendments agreed to

  14. Engrossed by House as amended

  15. Read third time and passed House (61-Y 33-N 0-A)

  16. Constitutional reading dispensed (on 1st reading)

  17. Referred to Committee on Commerce and Labor

  18. Fiscal Impact Statement from Department of Planning and Budget (HB483)

  19. Senate committee offered

  20. Reported from Commerce and Labor with substitute and rereferred to Finance and Appropriations (12-Y 3-N)

  21. Committee substitute printed 26109394D-S1

  22. Reported from Finance and Appropriations with substitute (10-Y 4-N)

  23. Committee substitute printed 26109533D-S2

  24. Rules suspended

  25. Constitutional reading dispensed (on 2nd reading) (37-Y 0-N 0-A)

  26. Passed by for the day (Voice Vote)

  27. Read third time

  28. Commerce and Labor Substitute rejected

  29. Finance and Appropriations Substitute agreed to

  30. Engrossed by Senate - committee substitute

  31. Passed Senate with substitute (34-Y 6-N 0-A)

  32. Senate substitute agreed to by House (87-Y 11-N 0-A)

  33. Fiscal Impact Statement from Department of Planning and Budget (HB483)

  34. Enrolled

  35. Bill text as passed House and Senate (HB483ER)

  36. Signed by President

  37. Fiscal Impact Statement from Department of Planning and Budget (HB483)

  38. Signed by Speaker

  39. Enrolled Bill communicated to Governor on March 31, 2026

  40. Governor's Action Deadline 11:59 p.m., April 13, 2026

  41. Governor's recommendation received by House

  42. Passed by for the day

  43. Passed by for the day

  44. Communicated to Governor

  45. Governor's Action Deadline 11:59 p.m., May 23, 2026

  46. Governor's Veto Received by House

  47. Vetoed by Governor

Verify the information

Our commitment to neutrality

We provide factual information only. We never tell you which politicians or bills to support, and we do not rank, score, or endorse anyone.